Processa Pharmaceuticals Inc. (PCSA)
Market Closed
16 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
2. 09
-0.12
-5.4299%
$
4.92M Market Cap
- P/E Ratio
- Div Yield
61,874 Volume
-7 Eps
$ 2.21
Previous Close Want to track PCSA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.
Zacks | 6 months ago
Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?
Processa Pharmaceuticals (NASDAQ: PCSA ) stock is rising higher on Tuesday after the company posted an update from the Food and Drug Administration (FDA). The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap).
Investorplace | 1 year ago
